- Home
- OXBR vs CLRB Comparison
OXBR vs CLRB Comparison
Compare OXBR & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OXBR
- CLRB
- Stock Information
- Founded
- OXBR 2013
- CLRB 2002
- Country
- OXBR Cayman Islands
- CLRB United States
- Employees
- OXBR N/A
- CLRB N/A
- Industry
- OXBR Property-Casualty Insurers
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- OXBR Finance
- CLRB Health Care
- Exchange
- OXBR Nasdaq
- CLRB Nasdaq
- Market Cap
- OXBR 15.1M
- CLRB 14.2M
- IPO Year
- OXBR 2014
- CLRB N/A
- Fundamental
- Price
- OXBR $2.30
- CLRB $5.06
- Analyst Decision
- OXBR Strong Buy
- CLRB Hold
- Analyst Count
- OXBR 1
- CLRB 2
- Target Price
- OXBR $5.00
- CLRB N/A
- AVG Volume (30 Days)
- OXBR 73.7K
- CLRB 97.0K
- Earning Date
- OXBR 11-12-2025
- CLRB 11-17-2025
- Dividend Yield
- OXBR N/A
- CLRB N/A
- EPS Growth
- OXBR N/A
- CLRB N/A
- EPS
- OXBR N/A
- CLRB N/A
- Revenue
- OXBR $1,983,000.00
- CLRB N/A
- Revenue This Year
- OXBR $497.99
- CLRB N/A
- Revenue Next Year
- OXBR $42.14
- CLRB N/A
- P/E Ratio
- OXBR N/A
- CLRB N/A
- Revenue Growth
- OXBR N/A
- CLRB N/A
- 52 Week Low
- OXBR $1.27
- CLRB $4.11
- 52 Week High
- OXBR $5.81
- CLRB $67.50
- Technical
- Relative Strength Index (RSI)
- OXBR 56.34
- CLRB 51.37
- Support Level
- OXBR $1.93
- CLRB $4.82
- Resistance Level
- OXBR $2.86
- CLRB $5.34
- Average True Range (ATR)
- OXBR 0.22
- CLRB 0.34
- MACD
- OXBR 0.04
- CLRB 0.05
- Stochastic Oscillator
- OXBR 39.78
- CLRB 68.85
About OXBR Oxbridge Re Holdings Limited
Oxbridge Re Holdings Ltd is a specialty property and casualty reinsurer. It provides reinsurance solutions through its subsidiary. It focuses on underwriting fully collateralized reinsurance contracts for property and casualty insurance companies in the Gulf Coast region of the United States, with an emphasis on Florida. Oxbridge specializes in underwriting medium frequency, high severity risks, where insufficient data exists to analyze effectively the risk/return profile of reinsurance contracts. The company manages its business on the basis of one operating segment, Property and Casualty Reinsurance.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.